NOPASS
Introducing NoPass™ RNAi
A First-in-Class Platform for Multi-Target Gene Silencing in Cancer
At Speratum Biopharma, we’ve developed NoPass™, a groundbreaking RNA interference (RNAi) platform engineered to overcome the limitations of traditional RNA-based therapies. Unlike conventional siRNAs or fragile endogenous microRNAs that act on a single target, NoPass™ functions as an intelligent control system—coordinating multiple cancer-related pathways with precision, stability, and safety.
Built from the ground up using proprietary scaffold architecture and design algorithms, NoPass™ represents a new class of therapeutic RNAi—purpose-built for complex disease systems like cancer
Why NoPass™ Is Different
Traditional RNAi drugs rely on single-gene targeting and require heavy chemical modifications for stability. NoPass™ is different. It was designed to address the multifactorial nature of cancer, targeting the root regulatory failures that drive tumor growth, resistance, and metastasis.
NoPass™ enables:
- Multi-pathway coordination – Hits several disease drivers simultaneously
- Non-canonical mechanisms – Avoids competition with native RNA machinery
- Stability without excessive chemistry – Reduces degradation risk
- Reduced off-target effects – Through intelligent scaffold and seed optimization
- Enhanced sensitivity to existing treatments – Reverses drug resistance
How NoPass™ RNAi Works
NoPass™ enhances the natural RNAi mechanism by optimizing how therapeutic RNAs are structured, stabilized, and delivered.
Step 1: Scaffold Design
Using our proprietary algorithm, we identify optimal 15-mer RNA fragments from disease-relevant mRNA sequences. These are scored and refined for structural conformation, seed complementarity, and predicted activity.
Step 2: Targeted Delivery
NoPass™ is delivered via Nano-In™, our proprietary biocompatible nanoparticle system, ensuring intact intracellular delivery to tumor cells.
Step 3: RISC Entry and Target Binding
Once inside the cell, NoPass™ interacts with the RISC complex. Unlike traditional siRNAs, our scaffolds are designed to engage multiple mRNA targets, ensuring broader regulatory control.
Step 4: Gene Silencing
Targeted mRNAs are cleaved and degraded—suppressing the production of proteins involved in cancer proliferation, invasion, and resistance.
Built for Oncology’s Toughest Challenges
NoPass™ powers our lead RNAi therapeutic, NM-198, which targets the most critical failure points in tumor biology:
🧬 Cell proliferation – Inhibits genes driving unchecked tumor growth
🧭 Metastasis and invasion – Blocks signals that enable cancer spread
🧪 Drug resistance – Resensitizes tumors to chemotherapy
🧠 Pathway modulation – Acts systemically across multiple interlinked targets
This systems-level approach is what sets NM-198 apart from single-pathway therapeutics.
Validated Across Tumor Models
Preclinical studies show that NM-198, enabled by NoPass™, consistently delivers:
✔ Significant tumor reduction in pancreatic, ovarian, lung, breast, gastric, and colon models
✔ Restoration of drug responsiveness in chemoresistant tumor lines
✔ Improved survival in animal studies
✔ High specificity with minimal off-target effects
Specific Cleavage Motifs
Enable precise cleavage and trimming of the passenger strand, preventing its incorporation into the RISC complex and minimizing off-target effects
Why NoPass™ RNAi Is a Breakthrough
Engineered from scratch
Not a derivative of miRNA or siRNA
Modular design
Capable of custom tuning for target, disease, or indication
Synthetic versatility
Stable, programmable, and adaptable
Patent-backed innovation
US20220145290A1: RNAi-mediated multi-site regulation
WO2022040594A1: Novel scaffolding for combinatorial RNAi
Patent coverage:
Secures Speratum’s innovative edge in RNAi technology, ensuring long-term market exclusivity and scientific leadership.
US20220145290A1 Patent Pending
Substrate sequence design for RNAi-mediated multi-site regulation of genomic and non-genomic RNAs.
WO2022040594A1 Patent Pending
Novel RNA scaffolding for combinatorial RNA interference therapies.
From Concept to Clinic: Designed for Impact
NoPass™ was not created as a workaround to existing RNA modalities. It was built to replace them. By addressing the core regulatory complexity of cancer, it represents a turning point in RNAi innovation.
And thanks to its durable stability, predictable delivery, and multi-pathway coverage, NoPass™ constructs may require less frequent dosing, providing improved convenience for patients.
The NoPass™ Advantage in One Line:
Engineered to be smarter. Designed to be safer. Built to silence cancer at its core.
Ready to Partner with the Future of RNAi?
Join Speratum Biopharma in advancing a new class of intelligent therapeutics designed to make cancer a disease of the past.